Tumor biomarker analysis from COLUMBUS part 1: Encorafenib plus binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma

被引：2

作者：

Dummer, R. ^{[1
]}

Pathan, N. ^{[2
]}

Deng, S. ^{[3
]}

Robert, C. ^{[4
,5
]}

Fernandez, A. M. Arance ^{[6
]}

de Groot, J. W. B. ^{[7
]}

Garbe, C. ^{[8
]}

Gogas, H. J. ^{[9
]}

Gutzmer, R. ^{[10
]}

Krajsova, I. ^{[11
]}

Liszkay, G. ^{[12
]}

Loquai, C. ^{[13
]}

Mandala, M. ^{[14
]}

Schadendorf, D. ^{[15
,16
]}

Yamazaki, N. ^{[17
]}

di Pietro, A. ^{[18
]}

Xie, T.

Ascierto, P. A. ^{[19
]}

Flaherty, K. ^{[20
]}

机构：

[1] Univ Spital Zurich, Klin Dermatol, Dermatol Dept, Zurich, Switzerland

[2] Pfizer, Translat & Immuno Oncol, Global Prod Dev, La Jolla, CA USA

[3] Pfizer, Oncol Res Unit, San Diego, CA USA

[4] Gustave Roussy, Dermatol, Villejiuf, France

[5] Paris Saclay Univ, Villejiuf, France

[6] Hosp Clin Prov Barcelona, Med Oncol Dept, Barcelona, Spain

[7] Isala Oncol Ctr, Med Oncol, Zwolle, Netherlands

[8] Univ Hautklin Tuebingen, Dermatol, Tubingen, Germany

[9] Natl & Kapodistrian Univ Athens, Dept Med 1, Athens, Greece

[10] Ruhr Univ Bochum Campus Minden, Johannes Wesling Med Ctr, Dermatol, Minden, Germany

[11] Univ Hosp Prague, Dermato Oncol, Prague, Czech Republic

[12] Natl Inst Oncol Hungary, Oncol Internal Med, Budapest, Hungary

[13] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dermatol, Mainz, Germany

[14] Univ Perugia, Med Oncol, Perugia, Italy

[15] Univ Hosp Essen, West German Canc Ctr, Dermatol, Essen, Germany

[16] German Canc Consortium, Partner Site Essen, Essen, Germany

[17] Natl Canc Ctr, Dermatol Oncol Dept, Tsukiji Campus,Chuo Ku, Tokyo, Japan

[18] Pfizer, Oncol Res & Dev, San Diego, CA USA

[19] IRCCS Fdn Pascale, Ist Nazl Tumori, Canc Immunotherapy & Dev Therapeut, Melanoma, Naples, Italy

[20] MGH Massachusetts Gen Hosp, Hematol Oncol, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.912

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

786O

引用

页码：S902 / S902

页数：1

共 50 条

[1] COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
Schadendorf, Dirk
Dummer, Reinhard
Flaherty, Keith T.
Robert, Caroline
Arance, Ana
de Groot, Jan Willem B.
Garbe, Claus
Gogas, Helen J.
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Yamazaki, Naoya
Queirolo, Paola
Guenzel, Carolin
Polli, Anna
Thakur, Mahgull
di Pietro, Alessandra
Ascierto, Paolo A.
EUROPEAN JOURNAL OF CANCER, 2024, 204
[2] Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma
Rose, A. A. N.
DRUGS OF TODAY, 2019, 55 (04) : 247 - 264
[3] Safety of encorafenib, binimetinib, plus cetuximab for Japanese patients with BRAF V600E metastatic colorectal cancer
Yamaguchi, Toshifumi
Daisuke, Kotani
Atsuo, Takashima
Takeshi, Kato
Toshiki, Masuishi
Yoshito, Komatsu
Manabu, Shiozawa
Taito, Esaki
Naoki, Izawa
Shinji, Takeuchi
Hideaki, Bando
Satoru, Iwasa
Hiroko, Hasegawa
Taroh, Satoh
Hiroya, Taniguchi
Takayuki, Yoshino
ANNALS OF ONCOLOGY, 2022, 33 : S479 - S479
[4] STARBOARD: encorafenib plus binimetinib plus pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma
Schadendorf, Dirk
Dummer, Reinhard
Robert, Caroline
Ribas, Antoni
Sullivan, Ryan J.
Panella, Timothy
McKean, Meredith
Santos, Edgardo S.
Brill, Kimberli
Polli, Anna
di Pietro, Alessandra
Ascierto, Paolo A.
FUTURE ONCOLOGY, 2022, 18 (17) : 2041 - 2051
[5] Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
Augustyn, Kourtney
Joseph, Jocelyn
Patel, Anisha B.
Razmandi, Azadeh
Ali, Amatul Noor
Tawbi, Hussein A.
MELANOMA RESEARCH, 2023, 33 (05) : 406 - 416
[6] Encorafenib, binimetinib, and cetuximab combination therapy for patients with BRAF V600E mutant colorectal cancer
Moro, Kazuki
Saiki, Takuro
Sasaki, Kenta
Matsumoto, Akio
Zhou, Qiliang
Nakano, Mae
Nakano, Masato
Matsumoto, Yoshifumi
Shimada, Yoshifumi
Moriyama, Masato
Wakai, Toshifumi
Saijo, Yasuo
ANNALS OF ONCOLOGY, 2022, 33 : S541 - S541
[7] Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study
Smit, E.
Ahn, M-J
Dagogo-Jack, I.
Felip, E.
Gelsomino, F.
Johnson, B.
Johnson, M.
Negrao, M. V.
Offin, M.
Ramalingam, S.
Sanborn, R.
Tsao, A.
Wilner, K.
Alcasid, A.
Usari, T.
Zhang, X.
Riely, G.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S77 - S78
[8] TREATMENT EXPERIENCE WITH ENCORAFENIB PLUS BINIMETINIB FOR BRAF V600-MUTANT METASTATIC MELANOMA: MANAGEMENT INSIGHTS FOR CLINICAL PRACTICE
Holbrook, Kourtney
Tawbi, Hussein
Joseph, Jocelyn
Patel, Anisha
Razmandi, Azadeh
Noor, Amatul
ONCOLOGY NURSING FORUM, 2021, 48 (02)
[9] A plain language summary of the 5-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
Dummer, Reinhard
Flaherty, Keith T.
Robert, Caroline
Arance, Ana
de Groot, Jan Willem B.
Garbe, Claus
Gogas, Helen J.
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
di Pietro, Alessandra
Cantey-Kiser, Jean
Edwards, Michelle
Ascierto, Paolo A.
FUTURE ONCOLOGY, 2023, 19 (16) : 1091 - 1098
[10] Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K-mutant advanced or metastatic melanoma
Schadendorf, D.
Flaherty, K. T.
Nathan, P.
Hersey, P.
Garbe, C.
Milhem, M.
Demidov, L.
Mohr, P.
Hassel, J. C.
Rutkowski, P.
Dummer, R.
Utikal, J.
Kiecker, F.
Larkin, J.
D'Amelio, A., Jr.
Huang, Y.
Mookerjee, B.
Robert, C.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →